Background: Liver pathology in cats represents a frequent clinical condition occurring in animals of any age. Dietary supplementation with hepatoprotective and antioxidant products could represent a beneficial strategy to prevent and treat these disorders. We Results: The oral supplementation with the silibinin-phosphatidylcholine complex significantly reduced the activity of liver enzymes in serum (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, γ -glutamyl transferase) and the content of total bilirubin, albumin, pre-and post-bile acids, in cats with hepatic lipidosis or
39 Results: The oral supplementation with the silibinin-phosphatidylcholine complex significantly 40 reduced the activity of liver enzymes in serum (alanine aminotransferase, aspartate 41 aminotransferase, alkaline phosphatase, γ -glutamyl transferase) and the content of total 42 bilirubin, albumin, pre-and post-bile acids, in cats with hepatic lipidosis or cholangitis, 43 normalizing their liver function parameters. Moreover, following the supplementation, the 44 appetite was restored in all cats and the frequent episodes of diarrhea and vomit reported at 45 inclusion almost disappeared. (Norton et al., 2016) . Icterus, polyuria, and polydipsia can be observed at any stage, 62 depending on the etiology of the liver disease (Norton et al., 2016) . The diagnosis and treatment 63 of canine and feline liver diseases have dramatically improved over the last 20 years due to the 64 growing interest in hepatic histology and the hard work of small animal pathologists and 65 clinicians to obtain a definitive diagnosis. In 2006, the World Small Animal Veterinary 66 Association (WSAVA) Liver Standardization Group proposed common guidelines for diagnosis 67 of liver diseases in dogs and cats, using both histological and clinical criteria (Rothuizen J, et al., 68 2006) . A retrospective Japanese study applying the WSAVA diagnostic criteria showed that the 69 most frequent canine liver disease was microvascular dysplasia (MVD) (29.4%), followed by 70 hepatitis (23.5%) including cholangiohepatitis and cholangitis (Hirose et al., 2014 (Center et al., 1993) . In all serious liver disorders, 81 blood analysis may reveal elevated activities of hepatic enzymes, such as alanine 82 aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-83 glutamyl transferase (GGT), and increased levels of bile acids (Center et al., 1993) . As liver 84 functions decrease, the risk for presence of free radicals and oxidative injury increases. Several 85 dietary supplements such as vitamins, L-carnitine, curcumin, and silymarin (extract of milk 86 thistle), through their antioxidant action, could prevent liver damage and promote hepatocellular 87 repair (Norton et al., 2016) . In this study, we evaluated the tolerability and efficacy of long-term 88 treatment with a multi-component, dietary supplement containing functional natural ingredients 89 with recognized hepatoprotective properties in cats suffering from liver diseases. 98 hepatoprotective products in the 30 days before inclusion; cats treated with antibiotics or anti-99 inflammatory drugs in the 2 weeks before inclusion. Owners were verbally informed about the 100 methods and objectives of the study, and had to provide consent before their cat was enrolled.
101 Blood parameters and urine analysis as well as clinical examination were performed at inclusion 102 time (T0) and after 7 (T7), 28 (T28), 60 (T60), 90 (T90) and 180 (T180) days from the initiation 103 of the study.
104 Treatment 105 The treatment consisted of GlutaMax ® FORTE paste or tablets. The paste was administrated up 106 to 28 days, subsequently, from days 29 to the end of experiment, the multi-component 107 formulation was administrated in form of tablets. 1 ml of paste per 3.5 kg body weight or 1 tablet 108 per 10 kg body weight were daily administrated directly into the mouth or mixed with food for 109 180 consecutive days. In case of severe anorexia, the paste was mixed with liquid food and 110 administrated through a nasogastric feeding tube.
111 The composition of the paste and tablets is reported in Table 1 Table 3 and Table 4 , respectively. Consistently 124 with the liver pathologic conditions, the levels of bilirubin, bile acids and liver enzyme activity 125 in serum (ALT, AST, ALP, GGT) were remarkably high at baseline. Moreover, both cats with 126 hepatic lipidosis as well as those with cholangitis presented at inclusion a mild hyperglycemia 127 and abnormal coagulation profile, particularly in the fibrinogen level. Following supplementation 128 with the multi-component product based on silibinin-phosphatidylcholine complex, the activity 129 of liver enzymes steadily decreased, starting from the seventh days of treatment until the end of 130 the study (T180), in both pathological conditions (Figure 1, 2, 3 and 4) . Also the other serum 131 biochemical parameters tend to normalize following the oral supplementation.
132 Among cats with hepatic lipidosis nobody showed appetite at the beginning of the trial. Due to 133 the severe anorexia 6/10 were fed through a nasogastric feeding tube. Moreover, at inclusion, 134 6/10 cats suffered from vomit and diarrhea episodes. Starting from T28 until the end of the study, 135 no cats with hepatic lipidosis were fed through a nasogastric feeding tube and vomit and diarrhea 136 episodes disappeared in all cats.
137 On the other hand, 80% of cats with cholangitis were fed by nasogastric feeding tube at inclusion 138 and 90% suffered from diarrhea and vomit. Starting from T60, all cats with cholangitis received 139 food and supplementation without the nasogastric tube. The frequency of diarrhea and vomit 140 episodes variably decreased during the study, and at T180 only 2 cats presented rare episodes.
141 Moreover, body weight and body condition significantly improved in all cats with cholangitis 142 (Table 4) . 143 
Ancillary analysis
144 At baseline, there were no difference in hepatic function between cats treated with Glutamax® 145 FORTE and controls (Table 5 ). However, 180 days since the institution of treatment, cats 146 receving Glutamax® FORTE experienced a more marked reduction in ALT, AST and alkaline 147 phosphatase, with respect to those on standard management (Table 6) . 153 2014). The use of natural products in the treatment of these diseases has a long history. These 154 products emerged as a promising source of relatively nontoxic compounds whose molecular 155 mechanisms of hepatoprotective activity is difficult to understood. In fact if several formulations 156 are pure substances with standardized formulas, most of them contain numerous constituents, 157 making it difficult to attribute biological activity and mechanism to a specific compound. 181 Moreover silibinin inhibits expression of the adhesion molecule selectin, necessary for leukocyte 182 migration (Hackett et al., 2013 ). An antifibrotic effect in the liver with limitation in conversion Table 2   Table 2 1 Table 3   Table 3 Table 3 . Changes in clinical, hematological, coagulative, serum biochemical and urine parameters in cats with hepatic lipidosis Hepatic lipidosis (n=10)   T0  T7  T28  T60  T90  T180  P-value Table 4   Table 4 Urine protein Table 5   Table 5 1 Table 5 . Markers of hepatic function of treated cats and controls at baseline. All data are 2 expressed as mean (SD). Table 6 Table 6
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